Krystal Biotech (KRYS) saw its KRYS analyst rating maintained at Buy while Jefferies raised the price target to $371 from $310 on February 17, 2026. This action keeps the stock in Buy territory but signals stronger near-term upside from Jefferies.
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
Gnosca double death on 13 February prompts a Ticino police update and raises Swiss public safety risks. Investors should watch municipal spending, insurer pricing, and ESG screens.
ALESA.PA stock jumps 25.22% intraday to €0.85 on EURONEXT; we review drivers, valuation, Meyka grade and price forecasts
ABZT stock update: price USD 0.000001, volume 28,500 on PNK 10 Feb 2026 — high-volume movers outlook
RSDFIN.BO stock jumps 19.99% pre-market on 13 Feb 2026 with volume 6,444; short-term momentum and a Meyka forecast to INR 132.44
Intraday update: Weimob (2013.HK) HKD 2.59 with heavy volume — 2013.HK stock intraday analysis and Meyka AI forecast
Explore the impacts of Ng Chee Khern’s retirement on Singapore’s defence and aerospace strategies.